Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8
30 Outubro 2023 - 9:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that it will host a conference call and live
webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide
a corporate update and discuss the Company's financial results for
the third quarter ended September 30, 2023.
A live audio webcast of the call be accessed by
visiting the investor relations section of the Company’s website,
www.avadel.com. A replay of the webcast will be archived on
Avadel’s website for 90 days following the event. Participants may
register for the conference call here and are advised to do so at
least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals
plcAvadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZTM, was approved by the U.S. Food &
Drug Administration (FDA) as the first and only once-at-bedtime
oxybate for the treatment of cataplexy or excessive daytime
sleepiness (EDS) in adults with narcolepsy. For more information,
please visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com (609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024